Clayton Medical Research Foundation Inc
- Assets
- $78.0m
- Revenue
- $3.0m
- Investments
- $0.0
- Employees
- 0
- Location
- Carson City, NV
- Founding
- 04/1988
- Data as of
- 12/2022
- EIN
- 51-0306704
Organization Overview
Clayton Medical Research Foundation Inc is located in Carson City, NV. The organization was established in 1988. According to its NTEE Classification (H05) the organization is classified as: Research Institutes & Public Policy Analysis, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Clayton Medical Research Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Clayton Medical Research Foundation Inc generated $3.0m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 4 years, the organization has seen revenues fall by an average of (11.7%) each year. All expenses for the organization totaled $2.9m during the year ending 12/2022. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
CLAYTON MEDICAL RESEARCH FOUNDATION, INC. WAS ESTABLISHED AS A CHARITABLE NON-PROFIT CORPORATION TO SUPPORT MEDICAL AND SCIENTIFIC RESEARCH.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE TUMOR TARGETING TOXINS GRANT TO THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, FUNDS RESEARCH DIRECTED TO THE DISCOVERY AND DEVELOPMENT OF COMPOUNDS FOR CANCER THERAPY, COMPOUNDS SYNTHESIZED WITH PROTEINS JOINED BY A SORTASE REACTION, AND COMPOUNDS WITH CANCER STEM CELL AND HORMONE TARGETING LIGANDS COUPLED WITH TOXINS FOR DELIVERY TO OVARIAN TUMORS AND OTHER EPITHELIAL TUMORS. PATENT APPLICATIONS HAVE BEEN FILED FOR THESE TECHNOLOGIES BY RESEARCH DEVELOPMENT FOUNDATION ("RDF"), A TAX-EXEMPT SUPPORTING ORGANIZATION OF THE FOUNDATION (SEE SCHEDULE R, PART III), AND COLLABORATIONS HAVE BEEN AND ARE BEING ESTABLISHED WITH OTHER SCIENTISTS AND WITH COMMERCIAL ENTITIES AND CONSULTANTS FOR MANUFACTURING AND DEVELOPMENT OF DRUGS FOR HUMAN CANCER INDICATIONS.
STF-1 AND GLUCOSE CONTROL GRANT TO THE SALK INSTITUTE FOR BIOLOGICAL STUDIES FOCUSES ON CHARACTERIZATION OF CELLULAR PROTEINS THAT MODULATE FATTY ACID METABOLISM IN MUSCLE AND FAT; CHARACTERIZATION OF A SIGNALING MODULE THAT PROMOTES BETA CELL SURVIVAL; AND THE ROLE OF PDX AND OTHER KNOWN AND NEW MOLECULAR SWITCHES IN PROMOTING BETA ISLET CELL PROLIFERATION AND INSULIN SECRETION IN THE PANCREAS AND LIVER.
A MEDICAL RESEARCH GRANT TO THE UNIVERSITY OF CALIFORNIA, IRVINE FOR RESEARCH COLLABORATION WITH THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER SAN ANTONIO INVOLVING THE DESIGN AND DEVELOPMENT OF NEW TECHNOLOGY AND DEVICES BASED ON THE USE OF LIGHT FOR DIAGNOSIS, GUIDANCE AND SURGERY IN CARDIOLOGICAL AND OTHER MEDICAL APPLICATIONS, INCLUDING POSSIBLE USE IN TREATMENT OF CORONARY TOTAL OCCLUSION AND CORONARY ARTERY DISEASES AND TECHNOLOGIES TO ALLOW STENTING INTRAVASCULAR CORONARY ARTERIES THAT ARE NARROWED OR BLOCKED DUE TO CALCIFICATION. RESEARCH TO DATE ON THIS PROJECT HAS RESULTED IN SEVERAL ISSUED PATENTS AND A NUMBER OF PENDING PATENT APPLICATIONS HAVE BEEN FILED. LICENSING DISCUSSIONS ARE CURRENTLY IN PROGRESS WITH A COMMERCIAL ENTITY THAT WILL TAKE ON THE CLINICAL DEVELOPMENT OF ONE OF THESE TECHNOLOGIES.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Robert M Wallace Trustee, President | OfficerTrustee | 8 | $12,969 |
Jarred W Sloan Trustee, Vice President, Treasurer | OfficerTrustee | 6 | $12,969 |
Lynn P Carter Trustee | Trustee | 4 | $12,969 |
Thomas J Brorby Trustee, Chairman | OfficerTrustee | 2 | $12,969 |
Brian W Crozier Trustee | Trustee | 2 | $12,969 |
Joan S Dunlap Vice President, Assistant Secretary | Officer | 4 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $0 |
| Total Program Service Revenue | $0 |
| Investment income | $1,852,220 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $1,116,001 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $2,968,221 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $2,408,327 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $64,845 |
| Compensation of current officers, directors, key employees. | $9,727 |
| Compensation to disqualified persons | $168,150 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $3,603 |
| Fees for services: Accounting | $13,131 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $162,788 |
| Fees for services: Other | $16,181 |
| Advertising and promotion | $0 |
| Office expenses | $4,331 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $21,000 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $75,576 |
| All other expenses | $0 |
| Total functional expenses | $2,947,932 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $136,071 |
| Savings and temporary cash investments | $3,245 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $411,296 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $50,252 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $77,396,148 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $77,997,012 |
| Accounts payable and accrued expenses | $5,890 |
| Grants payable | $2,346,000 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $2,351,890 |
| Net assets without donor restrictions | $62,440,507 |
| Net assets with donor restrictions | $13,204,615 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $77,997,012 |
Grants Awarded
Over the last fiscal year, Clayton Medical Research Foundation Inc has awarded $2,408,327 in support to 3 organizations.
| Grant Recipient | Amount |
|---|---|
THE SALK INSTITUTE PURPOSE: Medical research | $1,286,000 |
UNIV CALIF IRVINE PURPOSE: Medical research | $350,000 |
UNIVCALIF SAN DIEGO PURPOSE: Medical research | $772,327 |